Novartis to Seek FDA Emergency Use Approval for New COVID-19 Therapy

Novartis said on January 10 that positive data from a clinical trial of the COVID-19 therapeutic drug ensovibep prompted the company to exercise an antiviral licensing option from development partner Molecular Partners and subsequently seek approval for emergency use from US regulators. In a statement, Novartis confirmed its plans to pay about $163 million to … Read more